Investors in the US stock market relied more on US economic aid on Thursday and drove prices up a little further. Both the default values …
NEW YORK (dpa-AFX) – Investors in the US stock market relied more on US economic aid on Thursday and drove prices up a little further. Both the standard values and the technology indices gained, finally making up for their price losses on Tuesday after they had almost completely made up the day before.
The leading index Dow Jones Industrial (Dow Jones 30 Industrial) closed trading with an increase of 0.43 percent to 28,425.51 points. The broad S&P 500 advanced 0.80 percent to 3,446.83 points and the tech-heavy NASDAQ 100 gained 0.42 percent to 11,550.94 points.
Even the outcome of the US election on November 3rd, it seems to be losing its uncertainty, according to the current “Fuchs” letter. “The two presidential candidates Trump and Biden are pursuing very different directions, but the markets can expect that enormous sums of money will continue to be spent in both cases and will flow into the economy and into the markets,” the authors wrote on Thursday.
In the Dow, the IBM shares (IBM) stood out with price gains of almost six percent. Investors applauded because the IT group now wants to concentrate entirely on lucrative cloud businesses, which is why the division around network services for companies is to be split off and floated on the stock exchange as an independent company.
On the other hand, the shares of the Biotech-Company and Dow newbies Amgen at the end of the index. They responded to new study data on a drug against heart failure. JPMorgan analyst Cory Kasimov called the data disappointing.
The investment bank Morgan Stanley wants to take over the asset manager Eaton Vance for around seven billion US dollars. The shares of Eaton Vance then gained a little more than 48 percent, those of Morgan Stanley advanced by 0.6 percent.
At the world’s largest fast food company McDonald’s (McDonalds), the consequences of the corona pandemic are continuing to decline. In the third quarter, like-for-like sales worldwide fell by only 2.2 percent year-on-year. In the USA they even attracted. The group’s shares fell 0.3 percent on Thursday. They had been running strong lately, hitting a record high two days ago.
Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) rose 1.4 percent after filing an application with the U.S. FDA for emergency approval for its Covid-19 research treatment REGN-COV2. If the experimental antibody treatment is approved, the US government is committed to making the therapy available to all US citizens free of charge.
One euro cost 1.1759 US dollars after the US market closed. The European Central Bank (ECB) had set the reference rate at 1.1765 (Wednesday: 1.1770) US dollars and the dollar cost 0.8500 (0.8496) euros. The futures contract for ten-year Treasuries (T-Note-Future) rose by 0.15 percent to 138.91 points. The yield on ten year bonds was 0.765 percent./ajx/he
— By Achim Jüngling, dpa-AFX —
– .
